NCT05569408View on ClinicalTrials.gov

eVusheld Assessment reaL wORld Effectiveness in DoD Health System

CompletedOBSERVATIONAL

Enrollment

4,724

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

December 22, 2023

Study Completion Date

December 22, 2023

Conditions

COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease

Interventions

DRUG

EVUSHELD

Tixagevimab (AZD8895) and cilgavimab (AZD1061)

Trial Locations (1)

20889

Research Site, Bethesda

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY